Autologous Bone marrow-derived Mesenchymal Stem Cells (BMSC); Autologous Platelet-Rich Plasma (4 mL); Autologous Platelet-Rich Plasma (6 mL); Adipose Tissue Mesenchymal Stromal Cells (ADSC)
A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and Standard Therapy in Patients With Organic Erectile Dysfunction
Источник: ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–70 лет, только мужчины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 100 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (11.2026) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Предшествующее лечениеранее не лечились (первая линия)
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 9
Критерии включения
- Male sex, aged between 18 and 70 years.
- Confirmed diagnosis of organic erectile dysfunction (e.g., vasculogenic, diabetic, or post-traumatic) for a duration of at least 6 months.
- Documented resistance or inadequate response to first-line therapies, such as Phosphodiesterase type 5 inhibitors (PDE5i).
- IIEF-5 (International Index of Erectile Function) score < 21 at baseline.
- Stable relationship with a partner for the duration of the study.
- Ability to understand the study procedures and provide written informed consent.
Критерии невключения
- Psychogenic erectile dysfunction (not related to organic causes).
- Anatomical deformities of the penis (e.g., Peyronie's disease, severe penile curvature, or fibrosis that prevents injection).
- Uncontrolled systemic diseases, including decompensated diabetes mellitus (HbA1c > 9%), severe cardiovascular disease, or uncontrolled hypertension.
- History of pelvic malignancy (e.g., prostate or bladder cancer) or undergoing active radiation/chemotherapy.
- Active infection (local or systemic) or skin diseases at the site of the intended injection.
- Hematological disorders, such as severe anemia, coagulopathy, thrombocytopenia, or current use of anticoagulants that cannot be safely paused.
- Testosterone deficiency (Hypogonadism) that has not been stabilized by hormone replacement therapy.
- History of drug or alcohol abuse that may interfere with study compliance.
- Participation in another clinical trial involving experimental treatments for erectile dysfunction within the last 3 months.
Источник: ClinicalTrials.gov, NCT07544537 · запись обновлена в реестре 22 апреля 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 2
- Change from Baseline in International Index of Erectile Function (IIEF-5) Score — Baseline, 1 month, 3 months, 6 months, 9 months and 12 months post-treatment.
Цель исследования
Erectile dysfunction (ED) is a common condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It can significantly affect physical health, emotional well-being, and quality of life for both patients and their partners. Standard treatment options include medications such as phosphodiesterase type 5 inhibitors, vacuum devices, intracavernosal or transurethral therapies, and surgical implantation of penile prostheses. In recent years, low-intensity shock wave therapy has also been introduced as a treatment option. However, these approaches may have limitations in effectiveness, invasiveness, or long-term outcomes, highlighting the need for alternative therapies.
Advances in regenerative medicine have introduced new potential treatment strategies, including the use of autologous mesenchymal stem cells derived from bone marrow or adipose tissue. These therapies aim to improve tissue repair and restore erectile function. Previous preclinical and clinical studies suggest that mesenchymal stem cell therapy may be safe and effective, but direct comparisons between different sources of stem cells remain limited.
This prospective study aims to evaluate and compare the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells, adipose tissue-derived mesenchymal stromal cells, and platelet-rich plasma (PRP) therapy in patients with organic erectile dysfunction. A control group receiving standard conservative treatment, including low-intensity shock wave therapy, will also be included.
The study will be conducted in a population of patients in Kazakhstan and will assess outcomes before and after treatment to determine improvements in erectile function and overall patient well-being. The results may help identify more effective and regenerative treatment approaches for patients with organic erectile dysfunction.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07544537 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, сроки, число участников, спонсор, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.